Basic Study
Copyright ©The Author(s) 2019.
World J Hepatol. Jun 27, 2019; 11(6): 522-530
Published online Jun 27, 2019. doi: 10.4254/wjh.v11.i6.522
Table 1 Grade of hepatic encephalopathy in proton pump inhibitor users versus nonusers
Grade of HEPPI user
PPI nonuser
n = 75n = 28
Grade 115 (20.0)11 (39.3)
Grade 232 (46.6)13 (46.4)
Grade 318 (24.0)4 (14.3)
Grade 410 (13.4)0 (0)
Table 2 Participant characteristics
VariablesTotal, n = 103PPI user, n = 75PPI nonuser, n = 28P value
Age, yr, Mean ± SD58.3 (10.8)59.6 (10.6)55.3 (10.7)0.044a
Sex, male, n (%)71 (58.7)54 (63.5)17 (47.2)0.143
On lactulose, n (%)92 (76)63 (74.1)29 (80)0.599
Bleeding in last 12 mo, n (%)39 (32.2)26 (30.6)13 (36.1)0.703
Infection, n (%)
Clostridium difficile colitis5 (4.1)5 (5.9)0 (0)0.324
Pneumonia11 (9.1)10 (11.8)1 (2.8)0.220
Spontaneous bacterial peritonitis9 (7.4)5 (5.9)4 (11.1)0.533
Serum ammonia level, Mean ± SD61.1 (67.2)67.8 (67.8)45.5 (64.2)0.095
Grade of hepatic encephalopathy, Mean ± SD2.1 (0.9)2.3 (0.9)1.7 (0.7)0.001b
MELD score, Mean ± SD19.9 (7.2)19.7 (7.4)20.3 (6.7)0.687
Length of stay in d, Mean ± SD8.5 (7.0)8.3 (7.9)6.5 (3.7)0.046a
Required ICU, n (%)33 (27.3)27 (31.8)6 (16.7)0.138
Expired, n (%)11 (9.1)10 (11.8)1 (2.8)0.220
Table 3 Linear regression models, grade of hepatic encephalopathy
VariablesΒ ± SEP value
Model 1, demographic variables
Age-0.001 ± 0.0010.871
Sex0.062 ± 0.1670.710
PPI use0.607 ± 0.1800.001b
Model 2, medical comorbidities
Age0.002 ± 0.0080.787
Sex0.043 ± 0.1660.797
MELD Score0.020 ± 0.0110.079
PPI Use0.607 ± 0.179< 0.001b
Model 3, other medications
Age0.004 ± 0.0080.647
Sex0.033 ± 0.1640.839
MELD Score0.024 ± 0.0110.041a
Lactulose0.324 ± 0.1890.089
PPI use0.625 ± 0.178< 0.001b